Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 3/20 | 0.32 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101113 | 1.00 | CYP2A6 (0.35) | CYP2A6ALDH1A1ESR2PDE4BMALT1 | |
| SCHEMBL14895853 | 0.87 | CYP2A6 (0.35) | CYP2A6ALDH1A1ESR2PDE4BMALT1 | |
| SCHEMBL23076675 | 0.85 | MAOA (0.42) | CYP2A6ALDH1A1PDE4BCHRM1PDE4A | |
| SCHEMBL23030124 | 0.84 | PDE4B (0.49) | PDE4BCHRM1PDE4AADRA1APDE1A | |
| SCHEMBL31058250 | 0.82 | AR (0.37) | CYP2A6ESR2PDE4BCHRM1PDE4A | |
| SCHEMBL29358185 | 0.82 | CYP11B2 (0.38) | CYP2A6ALDH1A1ESR2PDE4BCHRM1 | |
| SCHEMBL30372881 | 0.82 | ALDH1A1 (0.36) | CYP2A6ALDH1A1ESR2PDE4BCHRM1 | |
| SCHEMBL156525 | 0.82 | CYP11B2 (0.38) | CYP2A6ALDH1A1ESR2PDE4BCHRM1 | |
| SCHEMBL22637023 | 0.82 | ALDH1A1 (0.36) | CYP2A6ALDH1A1ESR2PDE4BCHRM1 | |
| SCHEMBL10041745 | 0.82 | AR (0.37) | CYP2A6ESR2PDE4BCHRM1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107227-A1 | COMPOSITIONS COMPRISING USP1 INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | BEIGENE, LTD. (KY) | 2025-01-23 | — | — | US | disclosed |
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| US-20240083857-A1 | 2-Methyl-Quinazolines | Bayer Pharma AG (DE) | 2024-03-14 | — | — | US | disclosed |
| EP-4257588-A1 | SMALL MOLECULE INHIBITOR OF CATHEPSIN C AND MEDICINAL USE THEREOF | Reistone Biopharma Company Limited (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| WO-2022253326-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | 药捷安康(南京)科技股份有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-07-28 | — | — | US | disclosed |
| WO-2017170765-A1 | NOVEL NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2017-10-05 | — | — | WO | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649003-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2010-01-19 | — | — | US | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | PFIZER INC | 2008-05-08 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291640-B2 | Substituted triazole derivatives as oxytocin antagonists | PFIZER INC. (US) | 2007-11-06 | — | — | US | disclosed |
| WO-2005028452-A9 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LTD (GB) | 2005-07-21 | — | — | WO | disclosed |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | PFIZER INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | CYP2A6 3896/4885ALDH1A1 2544/4885ESR2 3250/4885 |
| US-20240083857-A1 | 2-Methyl-Quinazolines | NRAS, KRAS, KSR2 | CYP2A6 993/4885ALDH1A1 4417/4885ESR2 699/4885 |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | CYP2A6 4754/4885ALDH1A1 4554/4885ESR2 1168/4885 |
| US-20050107382-A1 | e.g. 2-(4-fluoro-2-methylphenyl)-5-(5-methoxymethyl-4-(6-methoxypyridin-3-yl)-4H-[1,2,4]triazol-3-yl)-pyridine; treatment of arousal disorder, orgasmic disorder, sexual pain disorder and premature ejaculation, preterm labor, appetite and feeding disorders, dysmenorrhoea, congestive heart failure, etc. | OXTR, OPRL1, NPY4R | CYP2A6 1859/4885ALDH1A1 2633/4885ESR2 113/4885 |
| US-20080108625-A1 | Substituted Triazole Derivatives as Oxytocin Antagonists | OXTR, PRLHR, KISS1R | CYP2A6 3418/4885ALDH1A1 3640/4885ESR2 76/4885 |
| US-20220235013-A1 | 2-METHYL-QUINAZOLINES | NRAS, KRAS, KSR2 | CYP2A6 993/4885ALDH1A1 4417/4885ESR2 699/4885 |
| US-20250026766-A1 | Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors | POLQ, POLK, POLI | CYP2A6 2716/4885ALDH1A1 2479/4885ESR2 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.